Tag Archives: MNKD

No Comments

Blogging Options: CBOE Mid-day Update 8.11.14

Volatility as an asset class MannKind (MNKD) is recently up 79c to $8.93 after the development-stage biopharmaceutical company announced that it has formed an exclusive licensing agreement for the development and commercialization of Afrezza inhaled insulin with Sanofi (SNY). August call option implied volatility is at 92, September is at 73, January is at 62; […]